Independent
Tenure on this board
2.1 yrs
Also a director at
Zentalis Pharmaceuticals Inc (ZNTL)
2 nominees · 4 ballot items.
Election of two Class III directors; ratification of PwC as independent auditors for 2026; non-binding advisory approval of named executive officer compensation (Say-on-Pay); non-binding advisory vote on frequency of future Say-on-Pay votes (Say-on-Frequency).
Vote to elect two Class III director nominees, Shannon Campbell and Kapil Dhingra, each to serve a three-year term until the 2029 annual meeting.
Ratify the audit committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Non-binding, advisory approval of the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.
Non-binding, advisory choice among one, two, or three years for the preferred frequency of future Say-on-Pay votes; board recommends every one year.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 18.43% | 10,563,103 | $22M |
| 2 | NEA Management Company, LLC | 7.76% | 4,448,757 | $9M |
| 3 | ACADIAN ASSET MANAGEMENT LLC | 4.10% | 2,348,651 | $5M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.23% | 1,850,468 | $4M |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 2.87% | 1,643,747 | $4M |
| 6 | DIMENSIONAL FUND ADVISORS LP | 2.19% | 1,252,142 | $3M |
| 7 | Connor, Clark Lunn Investment Management Ltd. | 1.85% | 1,058,397 | $2M |
| 8 | MACKENZIE FINANCIAL CORP | 1.47% | 844,835 | $2M |
| 9 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.46% | 834,570 | $2M |
| 10 | MARSHALL WACE, LLP | 1.43% | 817,735 | $2M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.